# Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

> **NCT03737643** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 1407 (actual)

## Conditions studied

- Advanced Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Durvalumab
- **DRUG:** Olaparib
- **DRUG:** Placebo olaparib
- **DRUG:** Durvalumab placebo
- **DRUG:** Carboplatin+Paclitaxel

## Key facts

- **NCT ID:** NCT03737643
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-04
- **Primary completion:** 2025-03-28
- **Final completion:** 2028-03-30
- **Target enrollment:** 1407 (ACTUAL)
- **Last updated:** 2025-01-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03737643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03737643, "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03737643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*